Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Gripovac 3   
Auth. number : EU/2/09/102
Active substance : Not available
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI09 - Immunologicals for suidae
Pharmacological subgroup: QI09A - Pig
Chemical subgroup: QI09AA - Inactivated viral vaccines
Chemical substance: QI09AA03 - porcine influenza virus
(See WHO ATCvet Index)
Indication: Active immunisation of pigs from the age of 56 days onwards including pregnant sows against swine influenza caused by subtypes H1N1, H3N2 and H1N2 to reduce clinical signs and viral lung load after infection. - Onset of immunity: 7 days after primary vaccination - Duration of immunity: 4 months in pigs vaccinated between the age of 56 and 96 days and 6 months in pigs vaccinated for the first time at 96 days and above.Active immunisation of pregnant sows after finished primary immunisation by administration of a single dose 14 days prior to farrowing to develop high colostral immunity which provides clinical protection of piglets for at least 33 days after birth.
Marketing Authorisation Holder: Merial
29 avenue Tony Garnier, 69007 Lyon, France
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/01/2010 Centralised - Authorisation EMEA/V/C/157 (2010)158 of 14/01/2010
08/12/2014 Centralised - Renewal EMEA/V/C/157/R/5 (2014)9461 of 04/12/2014